First Horizon Advisors Inc. Has $83,000 Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

First Horizon Advisors Inc. increased its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 26.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,049 shares of the company’s stock after acquiring an additional 222 shares during the quarter. First Horizon Advisors Inc.’s holdings in TransMedics Group were worth $83,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of TMDX. Bank of New York Mellon Corp increased its position in TransMedics Group by 91.4% during the third quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company’s stock worth $41,615,000 after acquiring an additional 363,012 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of TransMedics Group by 12.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,913 shares of the company’s stock worth $378,000 after acquiring an additional 763 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of TransMedics Group by 12.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 14,940 shares of the company’s stock worth $818,000 after purchasing an additional 1,700 shares in the last quarter. Park Avenue Securities LLC raised its stake in shares of TransMedics Group by 3.9% in the third quarter. Park Avenue Securities LLC now owns 11,729 shares of the company’s stock valued at $642,000 after purchasing an additional 442 shares in the last quarter. Finally, Emerald Mutual Fund Advisers Trust lifted its position in TransMedics Group by 0.6% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 356,747 shares of the company’s stock worth $19,532,000 after purchasing an additional 2,285 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Performance

Shares of NASDAQ:TMDX opened at $127.28 on Wednesday. The stock has a market capitalization of $4.19 billion, a P/E ratio of -374.35 and a beta of 1.87. The company has a current ratio of 9.72, a quick ratio of 8.76 and a debt-to-equity ratio of 3.18. TransMedics Group, Inc. has a 1-year low of $36.42 and a 1-year high of $132.96. The business has a 50-day moving average price of $87.41 and a two-hundred day moving average price of $78.57.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Tuesday, April 30th. The company reported $0.35 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.40. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 7.95%. The firm had revenue of $96.90 million during the quarter, compared to analyst estimates of $83.78 million. During the same quarter in the previous year, the business earned ($0.08) EPS. The business’s quarterly revenue was up 132.9% compared to the same quarter last year. Equities analysts predict that TransMedics Group, Inc. will post 0.62 earnings per share for the current year.

Insider Activity at TransMedics Group

In other TransMedics Group news, insider Tamer I. Khayal sold 63,260 shares of the stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $108.54, for a total value of $6,866,240.40. Following the completion of the sale, the insider now directly owns 9,792 shares in the company, valued at $1,062,823.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Tamer I. Khayal sold 63,260 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $108.54, for a total value of $6,866,240.40. Following the completion of the transaction, the insider now owns 9,792 shares in the company, valued at $1,062,823.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James R. Tobin sold 12,025 shares of the business’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $125.05, for a total transaction of $1,503,726.25. Following the completion of the sale, the director now directly owns 193,146 shares in the company, valued at $24,152,907.30. The disclosure for this sale can be found here. Insiders sold a total of 240,510 shares of company stock worth $24,452,647 in the last quarter. Corporate insiders own 7.00% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on TMDX. Morgan Stanley raised their price objective on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 28th. Oppenheimer upped their price target on TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. JPMorgan Chase & Co. upped their target price on shares of TransMedics Group from $105.00 to $127.00 and gave the stock an “overweight” rating in a report on Wednesday, May 1st. Piper Sandler reaffirmed an “overweight” rating and set a $120.00 price objective (up from $95.00) on shares of TransMedics Group in a research note on Wednesday, May 1st. Finally, TD Cowen increased their price target on TransMedics Group from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $119.00.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.